Drawing for SEQUADERMA

USPTO serial 79171753

SEQUADERMA

Reviewed by CopyMark Law Group

Reg. 5000628Status 404
Filing date
Status date
Registration date
Jul 19, 2016
Examiner
MCDOWELL, MATTHEW J
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SEQUADERMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Roberta S. Bren

Roberta S. Bren MUNCY, GEISSLER, OLDS & LOWE, P.C.4000 Legato RoadSuite 310Fairfax, VA 22033

Goods and services

ClassDescriptionStatusFirst use
003Non-medicated toiletries, non-medicated skin care preparations, face cleansers, non-medicated cosmetic preparations for skin care, beauty serums; beauty balms; non-medicated skin balms, skin toners, non-medicated exfoliating preparations for skin; gel eye masks, facial beauty masks; non-medicated skin creams, oils, lotions and sprays; non-medicated skin conditioners, skin moisturisers, eye cream, eye gel, lip moisturisers, lip balm, hand cream, body lotions, body wash, foot balms, body scrubs; essential oils, fragrances, soap, hair care preparations, dentifricesSECTION 71 - CANCELLED—
005Pharmaceutical preparations and substances for the treatment of pain and inflammation and diseases and disorders of the skin, eczema, psoriasis, acne, aging and thinning skin, rosacea and dermatitis; veterinary preparations for the treatment of pain and inflammation and diseases and disorders of the skin, eczema, psoriasis, acne, aging and thinning skin, rosacea and dermatitis; sanitary preparations for medical use; chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of pain and inflammation and diseases and disorders of the skin, eczema, psoriasis, acne, aging and thinning skin, rosacea and dermatitis; topical and parenteral preparations of vesicles in the nature of pharmaceutical or medical preparations for the treatment of pain and inflammation and diseases and disorders of the skin, eczema, psoriasis, acne, aging and thinning skin, rosacea and dermatitis; chemical preparations in the form of vesicles for medical and veterinary purposes for the treatment of pain and inflammation and diseases and disorders of the skin, eczema, psoriasis, acne, aging and thinning skin, rosacea and dermatitis; chemical membranes and chemical aggregates for medical and veterinary purposes for the treatment of pain and inflammation and diseases and disorders of the skin, eczema, psoriasis, acne, aging and thinning skin, rosacea and dermatitis; preparations of arachidonic acids for medical or pharmaceutical purposes; dispersions and dry preparations of liposomal active substances for use as a pharmaceutical, cosmetic and veterinary substance carrier; cosmeceutical preparations for medical use for the treatment of pain and inflammation and diseases and disorders of the skin, eczema, psoriasis, acne, aging and thinning skin, rosacea and dermatitis; local anesthetics; lipids for topical and parenteral use for medical or pharmaceutical purposes; medical or pharmaceutical creams, dispersions, lotions, ointments, gels, solutions, sprays, lacquers, foams and film forming solution for the treatment of ocular conditions, subcutaneous conditions such as cellulitis, dermal conditions associated with all layers of the skin, superficial and deep; medical or pharmaceutical surfactants for use in the treatment of diseases affecting the immune system, inflammatory diseases, diseases of the skin, hair and ear, the treatment of pain and inflammation, rosacea and skin redness, atopic eczema, dishydrotic hand eczema, seborrhoeic eczema, pruritus and other skin irritations, plaque type psoriasis, acne vulgaris, breakouts, spots and other blemishes, bacterial, fungal and viral infections related to the skin and/or its secretions, male pattern baldness, the treatment of wrinkles, eye-bags, pigmentation disorders and other dermatological conditions caused by skin aging and other forms of damage or where skin supporting structures become weakenedSECTION 71 - CANCELLED—
010Medical devices for topical use in the treatment of dermal conditions associated with all layers of the skin, superficial and deep, namely, medical devices in the nature of a carrier with nanostructures which cross through the skin, allowing subcutaneous adsorption for the treatment of conditions of the skin; molecular filtering devices for medical purposes, namely, a gel or cream preparation as a drug delivery device which filters through or migrates into the skin and has a physical therapeutic effect; medical, veterinary and surgical apparatus, instruments and devices, namely, a medical device in which vesicles act as a drug delivery device in the nature of non-pharmaceutical nanostructures that migrate through the skin and have a physical therapeutic effect; inhalers for medical purposes sold empty; injection apparatus, instruments and devices, namely, injection needles, injection instruments without needles; medical and surgical apparatus, instruments and devices for the administration of skin disease and aging therapy and prophylaxis preparations and substancesSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 12, 2026DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Feb 12, 2026DETHDEATH OF INTERNATIONAL REGISTRATION—
Nov 15, 2025DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Nov 15, 2025DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 31, 2023INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Oct 7, 2023INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Oct 7, 2023INPCINVALIDATION PROCESSED—
Oct 3, 2023INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Feb 3, 2023C71TCANCELLED SECTION 71—
Jul 19, 2021REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jan 3, 2020NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 9, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 23, 2016FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Dec 6, 2016FICSFINAL DISPOSITION NOTICE SENT TO IB—
Dec 6, 2016FIMPFINAL DISPOSITION PROCESSED—
Oct 19, 2016FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jul 28, 2016OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jul 19, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 3, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 3, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 20, 2016OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Apr 20, 2016OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Apr 13, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 31, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 15, 2016ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 15, 2016REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 15, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 15, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 15, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 2, 2015RFNTREFUSAL PROCESSED BY IB—
Sep 16, 2015RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 16, 2015RFRRREFUSAL PROCESSED BY MPU—
Sep 16, 2015RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 15, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 12, 2015MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 8, 2015DOCKASSIGNED TO EXAMINER—
Sep 8, 2015DOCKASSIGNED TO EXAMINER—
Sep 8, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 3, 2015REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance